Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model

Cellular Immunology

Volumn 260, Issue 1, 2009, Pages 33-38

  Matsuo, Yukiko ^a,b   Ishihara, Tsutomu ^c   Ishizaki, Junko ^a   Miyamoto, Ken ichi ^d   Higaki, Megumu ^c   Yamashita, Naomi ^b,c  

^a KANAZAWA UNIVERSITY   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Airway inflammation; Airway responsiveness; Betamethasone; Experimental asthma; Stealth nanoparticles

Indexed keywords

BETAMETHASONE SODIUM PHOSPHATE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BIOCOMPATIBILITY; BIODEGRADABILITY; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TISSUE LEVEL; ENCAPSULATION; EOSINOPHIL COUNT; FEMALE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SINGLE DRUG DOSE;

ANIMALS; ASTHMA; BETAMETHASONE; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GLUCOCORTICOIDS; INTERLEUKIN-13; INTERLEUKIN-4; LACTIC ACID; MICE; MICE, INBRED BALB C; NANOPARTICLES; OVALBUMIN; POLYETHYLENE GLYCOLS; POLYMERS;

MURINAE;

EID: 70350393883     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.07.004     Document Type: Article

References (33)

1. Adcock I.M., Caramori G., and Chung K.F. New targets for drug development in asthma. Lancet 372 (2008) 1073-1087
2. Holgate S.T. Airway inflammation and remodeling in asthma: current concepts. Mol. Biotechnol. 22 (2002) 179-189
3. Polosa R., and Morjaria J. Immunomodulatory and biologic therapies for severe refractory asthma. Respir. Med. 102 (2008) 1499-1510
4. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir. Med. 100 (2006) 1307-1317
5. Dunlap N.E., and Bailey W.C. Corticosteroids in asthma. South Med. J. 83 (1990) 428-432
6. Rossi G.A., Cerasoli F., and Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm. Pharmacol. Ther. 20 (2007) 23-35
7. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353 (2005) 1711-1723
8. Schacke H., Docke W.D., and Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96 (2002) 23-43
9. Konduri K.S., Nandedkar S., Duzgunes N., Suzara V., Artwohl J., Bunte R., and Gangadharam P.R. Efficacy of liposomal budesonide in experimental asthma. J. Allergy Clin. Immunol. 111 (2003) 321-327
10. Teshima M., Kawakami S., Fumoto S., Nishida K., Nakamura J., Nakashima M., Nakagawa H., Ichikawa N., and Sasaki H. PEGylated liposomes loading palmitoyl prednisolone for prolonged blood concentration of prednisolone. Biol. Pharm. Bull. 29 (2006) 1436-1440
11. Szebeni J., Baranyi L., Savay S., Milosevits J., Bunger R., Laverman P., Metselaar J.M., Storm G., Chanan-Khan A., Liebes L., Muggia F.M., Cohen R., Barenholz Y., and Alving C.R. Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J. Liposome Res. 12 (2002) 165-172
12. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., and Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (2007) 751-760
13. Ishihara T., Izumo N., Higaki M., Shimada E., Hagi T., Mine L., Ogawa Y., and Mizushima Y. Role of zinc in formulation of PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its release profile. J. Control Release 105 (2005) 68-76
14. Higaki M., Ishihara T., Izumo N., Takatsu M., and Mizushima Y. Treatment of experimental arthritis with poly(d,l-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann. Rheum. Dis. 64 (2005) 1132-1136
15. Sakai T., Kohno H., Ishihara T., Higaki M., Saito S., Matsushima M., Mizushima Y., and Kitahara K. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp. Eye Res. 82 (2006) 657-663
16. Ishihara T., Takahashi M., Higaki M., and Mizushima Y. Efficient encapsulation of a water-soluble corticosteroid in biodegradable nanoparticles. Int. J. Pharm. 365 (2009) 200-205
17. Ishihara T., Kubota T., Choi T., and Higaki M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharmacol. Exp. Ther. 329 (2009) 412-417
18. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., and Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263 (1994) 1600-1603
19. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., and Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84 (1995) 493-498
20. Yamashita N., Tashimo H., Matsuo Y., Ishida H., Yoshiura K., Sato K., Kakiuchi T., and Ohta K. Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific murine asthmatic model. J. Allergy Clin. Immunol. 117 (2006) 1040-1046
21. Trifilieff A., El-Hashim A., and Bertrand C. Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment. Am. J. Physiol. Lung Cell Mol. Physiol. 279 (2000) L1120-L1128
22. Blyth D.I., Wharton T.F., Pedrick M.S., Savage T.J., and Sanjar S. Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or anti-interleukin-5 antibody. Am. J. Respir. Cell Mol. Biol. 23 (2000) 241-246
23. R. Zaynagetdinov, S. Ryzhov, A.E. Goldstein, H. Yin, S.V. Novitskiy, K. Goleniewska, V.V. Polosukhin, D.C. Newcomb, D. Mitchell, E. Morschl, Y. Zhou, M.R. Blackburn, R.S. Peebles Jr., I. Biaggioni, I. Feoktistov, Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice, Am. J. Respir. Cell Mol. Biol. (2009). [Epub ahead of print].
24. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., Gibson P., Ohta K., O'Byrne P., Pedersen S.E., Pizzichini E., Sullivan S.D., Wenzel S.E., and Zar H.J. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 31 (2008) 143-178
25. Shefrin A.E., and Goldman R.D. Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients. Can. Fam. Physician 55 (2009) 704-706
26. Yih T.C., and Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J. Cell. Biochem. 97 (2006) 1184-1190
27. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv. 1 (2004) 321-333
28. Saari S.M., Vidgren M.T., Herrala J., Turjanmaa V.M., Koskinen M.O., and Nieminen M.M. Possibilities of formoterol to enhance the peripheral lung deposition of the inhaled liposome corticosteroids. Respir. Med. 96 (2002) 999-1005
29. Waldrep J.C., Gilbert B.E., Knight C.M., Black M.B., Scherer P.W., Knight V., and Eschenbacher W. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest 111 (1997) 316-323
30. Saari S.M., Vidgren M.T., Koskinen M.O., Turjanmaa V.M., Waldrep J.C., and Nieminen M.M. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 113 (1998) 1573-1579
31. Konduri K.S., Nandedkar S., Rickaby D.A., Duzgunes N., and Gangadharam P.R. The use of sterically stabilized liposomes to treat asthma. Methods Enzymol. 391 (2005) 413-427
32. Motomura G., Yamamoto T., Irisa T., Miyanishi K., Nishida K., and Iwamoto Y. Dose effects of corticosteroids on the development of osteonecrosis in rabbits. J. Rheumatol. 35 (2008) 2395-2399
33. Mann B.S., and Chung K.F. Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy. Respir. Res. 7 (2006) 59